If palliative care can "extend survival," where's the line with active treatment?
The survival benefit comes not from "treating more" but from "less futile treatment + earlier symptom control." The line isn't "treat vs not treat" but "which interventions carry burden exceeding benefit" — the same chemo may extend life first-line yet only add toxicity and shorten lucid time at the terminal stage. The key is to keep reassessing goals along the course, not barrel down one road.
Fear of opioid addiction is overstated at end of life, yet the societal opioid crisis is real — how is that not a contradiction?
Different contexts. The crisis stems mainly from long-term, high-volume community prescribing and misuse for non-cancer chronic pain (see Day 40); end-of-life analgesia is short-course, clearly indicated, professionally monitored use where clinical addiction is extremely rare. Acknowledging the crisis shouldn't breed "opioid phobia" that leaves dying patients in agony.
However detailed an advance directive is, it can't foresee every situation — does it still matter?
Precisely because it can't be exhaustive, "naming a proxy" often matters more than "a written checklist" — someone who knows your values can judge flexibly in the specific situation, while a checklist only covers preset scenarios. Ideal is both: the list draws the bottom lines, the proxy handles the gray zones. The document's core value isn't its clauses but that it forced the conversation.
"Dying at home" is treated as the mark of a good death, but for those living alone or with thin caregiving resources, is it instead a burden?
Yes. A good death is preference-driven, not dogma — with home hospice support, home is comfort; without care and with hard-to-control symptoms, a professional hospice unit may offer more dignity. Absolutizing "home" creates new guilt. The real question is "what does this person want, and under what conditions is it achievable."